Last updated on February 2020

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal Gastroesophageal and Renal Cancers


Brief description of study

This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.

Clinical Study Identifier: NCT03798626

Find a site near you

Start Over

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Mayo Clinic Arizona Reg-2

Phoenix, AZ United States
  Connect »

Honor Health Research Institute

Scottsdale, AZ United States
  Connect »